EICHORCondition: Autism Spectrum Disorder · Sponsor: Astrogen, Inc.
1. Study purpose: To demonstrate the superiority of AST-001 compared to placebo in improving core symptoms of autism spectrum disorder (ASD) in children with ASD. 2. Background: ASD is a neurodevelopmental disorder characterized by deficits in social communication and social interaction as well as restricted, repetitive patterns of behavior, interests, or activities. There are no approved medicines to treat the core symptom of ASD. Although these drugs and other psychotropic medications are associated with side effects, the use of psychotropic drugs to treat associated psychiatric comorbidities is common. AST-001 is developed to treat the core symptom of ASD. 3. Design: Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 clinical trial followed by an Open-Label Extension Treatment Period
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Soon Chun Hyang University Hospital Cheonan | Cheonan, Chungcheongnam-do, South Korea | — |
| Hallym University Medical Center | Anyang-si, Gyeonggi-do, South Korea | — |
| Samsung Changwon Medical Center | Changwon, Gyeongsangnam-do, South Korea | — |
| Pusan National University Yangsan Hospital | Yangsan, Gyeongsangnam-do, South Korea | — |
| Jeonbuk National University Hospital | Jeonju, Jeollabuk-do, South Korea | — |
| Chungnam National University Hospital | Daejeon, South Korea | — |
| Asan Medical Center | Seoul, South Korea | — |
| Hanyang University Seoul Hospital | Seoul, South Korea | — |
| Koera University Guro Hospital | Seoul, South Korea | — |
| Samsung Medical Center | Seoul, South Korea | — |
| The Catholic University of Korea, Seoul St. Mary's Hospital | Seoul, South Korea | — |
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06333964